From GlobeNewswire: 2025-06-06 09:39:00

Immix Biopharma, Inc. attended an in-person event led by FDA Commissioner Marty A. Makary, M.D., M.P.H. on June 5, 2025, at the FDA headquarters in Silver Spring, MD. The purpose of the meeting was to gather input from biotechnology and pharmaceutical leaders on modernizing the FDA’s regulatory framework for innovation and patient access to therapies. Immix Biopharma’s CEO expressed commitment to supporting an efficient regulatory environment. The company is developing cell therapies, with their lead candidate, NXC-201, being evaluated in a U.S. multi-center study for AL Amyloidosis. NXC-201 has received regulatory designations and presented positive interim results.

Immix Biopharma, Inc. participated in an FDA CEO forum to discuss modernizing the regulatory framework for innovation and patient access to therapies. The company’s lead candidate, NXC-201, a CAR-T cell therapy, is being studied for AL Amyloidosis and has shown positive interim results. Regulatory designations have been granted for NXC-201, highlighting its potential in treating serious diseases. The company is committed to accelerating patient access to safe and effective therapies. CEO Ilya Rachman and CFO Gabriel Morris expressed gratitude for the collaborative discussion at the FDA event.

Immix Biopharma, Inc. attended an FDA CEO forum to discuss modernizing regulatory frameworks for therapies. The company’s lead candidate, NXC-201, a CAR-T cell therapy, is being studied for AL Amyloidosis. Positive interim results have been presented, and regulatory designations have been granted for NXC-201. The company is dedicated to accelerating patient access to safe and effective therapies. CEO Ilya Rachman and CFO Gabriel Morris were thrilled to participate in the collaborative discussion at the FDA event.



Read more at GlobeNewswire: Immix Biopharma Attends FDA CEO Forum in Washington DC